Optical coherence tomography of basal cell carcinoma: influence of location, subtype, observer variability and image quality on diagnostic performance*

J. Holmes ^(b), ¹ T. von Braunmühl, ² C. Berking, ² E. Sattler ^(b), ² M. Ulrich, ³ U. Reinhold, ⁴ H. Kurzen, ⁵ T. Dirschka, ⁶ C. Kellner, ⁷ S. Schuh⁸ and J. Welzel⁸

¹Michelson Diagnostics Ltd, Maidstone, Kent, U.K.

²University Hospital Munich, Department of Dermatology, Munich, Germany

³Private Dermatology Office/CMB Collegium Medicum Berlin GmbH, Berlin, Germany

⁴Dermatology Center Bonn Friedensplatz, Bonn, Germany

⁵Private Dermatology Office, Freising, Germany

⁶Private Dermatology Office, Wuppertal, Germany

⁷St Bernard-Hospital, Kamp Lintfort, Germany

⁸General Hospital Augsburg, Department of Dermatology and Allergology, Augsburg, Germany

Summary

Correspondence

Jon Holmes. E-mail: jon.holmes@vivosight.com

Funding sources

This study was funded by Michelson Diagnostics Ltd (MDL). MDL was not involved in the design or conduct of the study. The lead author of this paper is an employee of MDL and led the data analysis under the supervision of the last author.

Conflicts of Interest

J.H. is an employee and shareholder of Michelson Diagnostics Ltd (MDL), who manufacture the optical coherence tomography equipment used in the study. M.U. has been paid by MDL for lectures; is a stakeholder in CMB Collegium Medicum Berlin GmbH; has been involved in clinical trials for LEO Pharma; and has given paid lectures for Almirall, Galderma, LEO Pharma and Mavig GmbH. T.v.B. has received speaker's honoraria from Agfa HealthCare GmbH, LEO Pharma and Roche Pharma; and has been involved in clinical trials sponsored by Agfa HealthCare GmbH and Mavig GmbH. H.K. is a paid advisor to MDL; has received speaker's honoraria from MDL, Almirall Hermal, AbbVie, Galderma and LEO Pharma; and has been involved in clinical trials for Eli Lilly Pharma, Novartis and AbbVie. T.D. has received advisory board honoraria from Almirall Hermal, Biofrontera, Galderma, Meda Pharma, Scibase, and Background We previously described the principal results from an observational, prospective, multicentre, clinical trial of the diagnostic value of optical coherence tomography (OCT) for basal cell carcinoma (BCC) in a clinical setting. In this trial, much additional useful information was gathered that warranted further analysis, presented here.

Objectives To investigate the influence of candidate diagnostic criteria, OCT image quality, lesion location, and observer confidence and interobserver variability on the diagnostic performance of OCT, and to assess its potential use for diagnosis of BCC subtypes.

Methods A total of 234 clinically unclear 'pink lesions' were evaluated in three steps: after clinical examination, after adding dermoscopy and after adding OCT. In addition to the diagnoses (including lesion subtype), observers recorded which of 15 diagnostic criteria the OCT image contained, their confidence in the diagnoses, the OCT image quality and the anatomical location of the lesion.

Results Diagnostic performance of OCT did not depend on the lesion's anatomical location. Good OCT image quality was correlated with improved diagnostic performance, but diagnostic performance for lesions with mediocre image quality was still better than by clinical and dermoscopic examination. The main reason for reduced image quality was superficial scales and crusting. Observer confidence in diagnosis was correlated with diagnostic performance. Interobserver diagnostic performance was consistently higher than clinical examination and dermoscopy across all sites. BCC subtype could be determined with moderate accuracy, but further independent image markers are required.

Conclusion OCT is useful in the diagnosis of BCC.

What's already known about this topic?

• Optical coherence tomography (OCT) is an emerging imaging modality that has been shown to have utility in the noninvasive diagnosis of basal cell carcinoma

Allergan; and has received speaker's honoraria from Almirall Hermal, Biofrontera, Galderma, Meda Pharma and Janssen-Cilag. C.B. has received speaker's and advisory board member's honoraria from Almirall, Biofrontera, Galderma and LEO Pharma; and has been involved in clinical trials sponsored by Biofrontera and LEO Pharma.

*Plain language summary available online

DOI 10.1111/bjd.16154

(BCC), and is more sensitive and more specific than clinical or dermoscopic examination alone.

What does this study add?

- Lesion location does not affect diagnostic performance with OCT.
- Poor OCT image quality is associated with superficial scales and crusting, reducing diagnostic performance, but in these cases diagnosis with OCT is better than by clinical or dermoscopy examination alone.
- Observers' diagnostic confidence increases when using OCT and their performance reflects this.
- Diagnostic performance is consistent between trained observers.
 - BCC subtype can be diagnosed from OCT images with moderate accuracy.

Optical coherence tomography (OCT) is gaining acceptance as a useful device to aid in the diagnosis of basal cell carcinoma (BCC). Several studies have been published demonstrating that OCT improves diagnostic accuracy compared with clinical and dermoscopic methods alone.^{1–5} For example, the baseline results in a previous report of our study are reproduced in Table 1.⁴

However, further work is required to determine the key factors that affect diagnostic performance with OCT, the most useful OCT image markers, interobserver variability, and the potential to identify reliably and accurately BCC subtypes. To answer these questions, further analysis of the dataset collected in our study was performed and reported herein.

Materials and methods

This was an investigator-initiated, phase IV, observational, prospective, multicentre trial conducted in six institutions in Germany from April 2013 to March 2014. Michelson Diagnostics Ltd (previously based in Orpington, U.K. and now in Maidstone, U.K.) provided the OCT equipment. The details of the multibeam 'VivoSight' OCT equipment are described elsewhere.⁶

Inclusion criteria for the study were the presence of a clinically unclear erythematous papule or plaque ('pink lesion') with clinical suspicion of BCC. Lesions that were clinically obvious BCCs and pigmented lesions were excluded from the

Table 1 Diagnostic performance of clinical examination, dermoscopy and optical coherence tomography (OCT; n = 234)

Clinical	Dermoscopy	OCT
90	91	96
29	54	75
66	75	85
65	79	92
66	76	87
	Clinical 90 29 66 65 66	Clinical Dermoscopy 90 91 29 54 66 75 65 79 66 76

Data are % (n = 234). PPV, positive predictive value; NPV, negative predictive value.

study. Patients had to be 18 years of age or older and give written informed consent; patients with unstable or uncontrolled clinically significant medical conditions were excluded.

Initially, observers recorded their clinical diagnosis, including whether or not a BCC, the BCC subtype or other lesion type, and their confidence in this diagnosis expressed as a percentage. Consecutively, dermoscopy was performed and the revised conclusions and diagnostic confidence recorded. Finally, the lesion was scanned with OCT and the evaluation was performed once more. Additionally, the assessment of OCT image quality for the lesion was documented on a 4-point scale (excellent/good/mediocre/poor). It was also recorded which of 15 'image biomarkers' that might possibly relate to BCC diagnosis were present in the OCT images, in the observer's judgement. Finally, the lesion was either biopsied (37% by shave biopsy, 29% by punch biopsy) or excised (34%). All assessments were documented before histological results were available.

A total of 256 lesions were examined. Histology was missing for 21 lesions, and one lesion lacked OCT and dermoscopy, leaving 234 lesions with data from clinical, dermoscopic and OCT examination. For two of these lesions, the anatomical location was not recorded and for 13 lesions the OCT image quality was not recorded. Of the 234 lesions, 141 (60.2%) were identified as BCC by histological analysis.

We analysed the data from these 234 lesions to assess the dependence of diagnostic performance upon (i) anatomical location (trunk/head/limb); (ii) OCT image quality; (iii) observer confidence level in the diagnosis; (iv) interobserver variability; and (v) lesion type and subtype. We also performed univariate logistic regression analysis of the image biomarkers to assess which were statistically significant for each subtype, and then calculated the accuracy of identification of the BCC subtype for the 141 histologically identified BCCs. We used the XLSTAT statistical analysis Excel add-in (Addinsoft, New York, NY, U.S.A.) to perform univariate logistic regression analysis of the dataset.

Local ethics committees approved the research protocol and all research was conducted according to the principles of the Declaration of Helsinki.

Results

Lesion location

Table 2 shows the diagnostic performance of each technique, grouped into the main anatomical areas for lesion location. For two lesions, the location was not recorded.

No significant variation in OCT diagnostic performance was observed between lesions located on the head and limbs. The calculated specificity for lesions on the trunk was a little lower than for head and limbs but still just within the limits of statistical variability for this small sample size (P < 0.05). However, it is noticeable that specificity for trunk lesions was also lower for dermoscopy owing to high false-positive diagnoses of actinic keratoses as BCCs.

Optical coherence tomography image quality

The observers graded OCT image quality as poor, mediocre, good or excellent, based on their experience. Figures 1–3 are examples of excellent image quality; Figures 4 and 5 are examples of mediocre and poor image quality, respectively. Table 3 shows OCT diagnostic performance vs. OCT image quality.

Only two lesions were classified as having poor image quality; a further 13 were not graded. The results show that lower OCT image quality adversely affects diagnostic performance. However, specificity and negative predictive value (NPV) remain higher than calculated for clinical examination or dermoscopy, even for lesions with mediocre image quality.

We examined the data for reasons why the OCT image quality might be reduced. We noticed that medium or poor OCT image quality was associated with lesions exhibiting superficial scales or crusting (78%) or thickened epidermis (76%), whereas the proportion of lesions with these properties fell to 54% and 53% for good OCT image quality, respectively, and to 35% and 26% for excellent OCT image quality, respectively. Thus, poor image quality was associated with superficial scales or crusting and a thickened epidermis.

Diagnostic confidence

Each observer recorded an estimate of their own confidence in the diagnosis, for each lesion, in a three-step model: for clinical examination alone, after adding dermoscopy and then after using OCT in addition to clinical and dermoscopy examinations. The average diagnostic confidence for the clinical diagnosis of BCC was 59%; additional dermoscopic evaluation improved this slightly to 64% and additional OCT increased it to 83%. These results mirror the improvements in actual diagnostic accuracy achieved (67% for clinical; 77% for additional dermoscopy; 88% for additional OCT), suggesting that the observers were able to assess quite accurately their own diagnostic ability.

Table 4 shows the diagnostic performance for lesions for each of three bands of 'OCT diagnostic confidence'.

The table shows that diagnostic accuracy, NPV, positive predictive value and sensitivity all improve with diagnostic confidence. The anomalously low specificity for the 'very high' confidence band is related to the small size of the number of true-negative and false-positive lesions (3 and 10, respectively). In the highest confidence category, there were no false negatives, resulting in 100% sensitivity and NPV for these lesions.

Interobserver variability

Table 5 shows the variation in diagnostic performance using OCT between five observers. The sixth observer did not examine enough lesions to provide a useful sample. The 95% confidence interval (CI) is also given for the global result. Because of the prospective nature of the study and to reflect the usual workflow of diagnosis, the observers assessed only their own OCT images. Therefore, the number of images varied between the observers, depending of the number of cases at each centre.

Statistically, the results are consistent with the calculated 95% CI. Overall accuracy was high for all observers, with little variation. These results suggest that the OCT imaging criteria for BCC diagnosis were effectively learned and then applied consistently by each observer.

Lesion type and subtype

We analysed the diagnostic performance by lesion type and subtype. For each histologically confirmed lesion class, we calculated the diagnostic performance for each method (proportion of total number of confirmed lesions of that subtype that

Table 2 Diagnostic performance by anatomical location

Clinical OCT Dermoscopy Trunk Head Limb Trunk Head Limb Trunk Head Limb Lesions (n) 70 97 65 70 97 65 70 97 65 92 94 88 89 96 96 94 Sensitivity 84 94 Specificity 26 34 30 26 71 57 68 80 80 PPV 77 77 80 70 89 87 85 64 61 NPV 81 92 56 61 82 63 81 87 94

Data are % unless otherwise indicated (n = 232). OCT, optical coherence tomography; PPV, positive predictive value; NPV, negative predictive value.



Fig 1. Example of a nodular basal cell carcinoma with typical characteristics, such as a poorly defined dermoepidermal junction (white line and white arrow), dark ovoid structures (+), ovoid structures with bright centre (black asterisk), black areas corresponding to cysts (white dashed circle) and surrounding bright stroma (white asterisk). Scale bar = 1.0 mm.



Fig 2. Superficial basal cell carcinoma (BCC). An example of tumour bulge intruding into the dermis (arrows) with an underlying dark border (asterisk), which are typical characteristics of superficial BCCs. Scale bar = 1.0 mm.



Fig 3. Infiltrative basal cell carcinoma (BCC). The characteristic feature of an infiltrative BCC is shown, the 'shoal of fish' (circle) consisting of clusters of narrow elongated dark structures (arrows). Scale bar = 1.0 mm.



Fig 4. Example of mediocre image quality due to presence of crusting/scales (arrows). Scale bar = 1.0 mm.

were correctly identified as BCC, or, for non-BCC types, as not BCC). The results are shown in Table 6, which also shows the number of histologically confirmed lesion types and subtypes in the sample set. The most common BCC subtype was superficial BCC (44% of all BCCs), followed by nodular BCC (22% of all BCCs) and then infiltrative. 'Other BCC' included two pigmented BCCs, five cystic BCCs, five exulcerated BCCs and seven multicentric BCCs.



Fig 5. Example of poor image quality due to ulceration with fibrine layers/exudation. Scale bar = 1.0 mm.

In Table 6, a low result means that subtype is challenging to diagnose as BCC, or that type is difficult to diagnose as not BCC, and a high result means that it is easy to diagnose correctly as BCC or not BCC. For example, 100% of the 12 infiltrative BCCs were identified as BCC by all three methods, but clinical diagnosis correctly identified only 39% of actinic keratosis as not BCC vs. 81% with OCT. For all BCC subtypes and other lesion types, diagnostic performance was higher with OCT.

These results suggest that OCT aids diagnosis of BCC for all BCC subtypes and that OCT also aids correct diagnosis of other lesion types as not BCC.

The observers were asked to indicate which of 15 image 'biomarkers' were present in the OCT images. The candidate biomarkers were selected prospectively based upon the

 Table 3 Diagnostic performance vs. optical coherence tomography (OCT) image quality

	OCT image quality					
	Excellent	Good	Mediocre	Poor	Not graded	All
Lesions (n)	23	138	58	2	13	234
Confirmed BCC	78	63	50	100	53	60
Sensitivity	100	98	86	100	100	96
Specificity	60	84	66	NA	83	75
PPV	90	91	71	100	88	85
NPV	100	96	83	NA	100	92

Data are % unless otherwise indicated (n = 234). BCC, basal cell carcinoma; PPV, positive predictive value; NPV, negative predictive value; NA, not applicable.

observers' experience and from previously published research.^{7–13} Our objective was to determine which OCT image biomarkers are of most diagnostic value, and also to find out if there are clear differences between BCC subtypes. A perfect biomarker would be present in all BCC OCT images and in no non-BCC images, or vice versa. A biomarker with little value appears equally often in both BCC and non-BCC lesions. The biomarkers were assessed by comparison with the healthy adjacent skin of the same participant.

Table 7 shows, for each biomarker and each classification, whether it was positively or negatively correlated, and if so whether strongly correlated with statistical significance (P < 0.05) or weakly correlated (P < 0.15). A blank entry indicates that the biomarker was only very weakly correlated or not correlated.

For identifying BCCs, the most useful positively correlated image features are ovoid structures (with or without bright centres), dark borders to the dermis, black areas/cysts and bulges/cones intruding into the dermis. A thickened epidermis was negatively correlated.

Concerning subtypes of BCC the most useful markers for the nodular subtype were the presence of ovoid structures and, especially, the presence of black areas/cysts. The latter feature was a powerful discriminator vs. the superficial BCC subtype for which this feature was negatively correlated. Other useful features for superficial BCC subtype were the presence of a dark border to the dermis and the presence of bulges/cones extending from the epidermis into the dermis. Negatively correlated features included thinned epidermis and surface scales. The infiltrative BCC subtype was distinguishable only by the presence of 'shoal of fish'-like narrow, elongated structures in the dermis.

Table 4 Diagnostic performance vs. observer confidence in optical coherence tomography diagnosis

	Low confidence		High confidence	Very high confidence
	(< 70%)	Medium confidence (70–80%)	(80–90%)	(95–100%)
No. of lesions (% of total)	49 (21)	56 (24)	42 (18)	87 (37)
Sensitivity	81	95	96	100
Specificity	71	76	88	77
PPV	68	72	93	96
NPV	83	96	93	100
Accuracy	76	84	93	97

Data are % unless otherwise indicated (n = 234). PPV, positive predictive value; NPV, negative predictive value.

Table 5 Variation in diagnostic performance with observer

Observer	1	2	3	4	5	All (95% CI)
Lesions (n)	91	35	28	42	36	232
Sensitivity	95	100	96	94	96	96 (91–98)
Specificity	67	79	80	89	80	75 (65–83)
PPV	83	82	93	89	90	85 (79–90)
NPV	88	100	89	94	92	92 (84–97)
Accuracy	85	89	92	91	90	87 (83–91)

Data are % unless otherwise indicated. CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value.

Table 6 Accuracy

Lesion type	n	Clinical	Dermoscopy	OCT
BCC (all types)	143	90	90	96
Nodular	32	88	91	97
Superficial	63	92	87	95
Infiltrative	12	100	100	100
Other type	23	91	96	96
Type not recorded	13	69	95	92
Not BCC (all types)	91	31	56	77
Actinic keratosis	36	39	58	81
Morbus Bowen	16	38	56	81
Seborrhoeic keratosis	5	60	60	100
Eczema	6	17	33	67
Other lesion type	28	14	57	68

Data are % (n = 234). OCT, optical coherence tomography; BCC, basal cell carcinoma.

Table 7	Image	biomarker	correlation	with	histological	subtype
---------	-------	-----------	-------------	------	--------------	---------

Figures 1–3 show typical OCT images of nodular, superficial and infiltrative BCC subtypes exhibiting these characteristic features.

We also examined the false-negative and false-positive OCT results for insight into why the misdiagnoses occurred. There were six false-negative OCT diagnoses. All six had superficial scales/crust marker; as a result, four of them had only 60% observer confidence, the other two 80%. Four of them had 'broken/poorly defined dermoepidermal junction (DEJ)', which is a marker for BCC, but none had dark or bright-centred ovoid structures or dark dermis borders. Just one of the false negatives had black areas/cysts, a strong marker for nodular BCC. All six were histologically identified as superficial BCC. In summary, the observers did not see the significant markers for BCC, probably because of the superficial crusting, and could not make a positive identification of BCC on a broken DEJ alone.

There were 22 OCT false positives, of which the majority (n = 12) were misdiagnosed as superficial BCC, three as nodular, four as infiltrative, one as other and two not specified. The histological identification of these lesions included actinic keratosis, lentigo solaris, scars, granuloma, lichen planus, and sebaceous and adnexal dysplasia. The most common OCT image markers of these false-positive lesions were thickened epidermis (70%), broken/poorly defined DEJ (60%), dark ovoid structures (50%). We found that 17 of the 22 (77%) OCT false positives had at least one of dark ovoid structures, dark borders and ovoid structures with bright centres. It is not

	BCC (all subtypes)	Nodular	Superficial	Infiltrative
Epidermis				
1. Superficial scales/crusts	/	/	()	/
2. Thickened epidermis	()	/	/	/
3. Thinned epidermis	(-)	/	()	/
4. Bright structures (horn-cysts)	/	/	/	/
5. Elongated rete ridges	(-)	/	(-)	/
6. Bulges/cones intruding into	(++)	/	(++)	/
dermis with underlying shadows				
DEJ				
7. DEJ well defined	/	/	/	/
8. DEJ broken/poorly defined	(++)	(++)	/	/
Dermis				
9. Dark ovoid structures	(+)	(++)	/	/
10. Dark border	(++)	/	(++)	/
12. Ovoid structures with bright centres	(++)	(++)	(+)	/
13. Prominent vessels	/	/	/	/
14. Black areas/cysts	(++)	(++)	()	/
15. Bright stroma	(-)	(+)	/	/
16. Narrow, elongated dark structures ('shoal of fish')	/	/	(-)	(++)

BCC, basal cell carcinoma; DEJ, dermoepidermal junction. (++), strongly correlated (P < 0.05); (+), weakly correlated (P < 0.05-0.15); (-), weakly anticorrelated (biomarker not present; P < 0.05-0.15); (--), strongly anticorrelated (biomarker not present; P < 0.05); (/), no, or very weak correlation or anticorrelation.

surprising – and perhaps inevitable – that these were identified as BCCs.

The univariate logistic regression produced a predictive model for identifying the BCC subtype from the image markers. From the statistics of markers in each subtype, it calculates weights for each marker and then, for a given lesion, the resulting probability that it is that subtype. The most probable subtype is then the model prediction.

The model prediction was compared with the performance of the observers in identifying BCC subtype based on their clinical assessment, dermoscopy and, finally, OCT. The number of correct predictions was calculated as a percentage of the total number of histologically confirmed lesions of that subtype (see Table 8).

The best results were obtained by the observers using OCT, not by the regression model. This could be for a number of reasons: (i) the observers might be using other additional image markers, based on their experience; (ii) the observers may not have recorded the presence of the markers on the case report forms with consistent accuracy, leading to a biased model; (iii) there may be too few examples in the dataset to enable an accurate model (especially for the infiltrative BCC subtype).

Nevertheless, the observers' subtype estimation was only 62–72%, i.e. incorrect in over a quarter of all cases. Further work will need to be done to find additional independent biomarkers to improve on these data.

Discussion

This detailed analysis has revealed some potentially useful criteria that may be suitable to apply when using OCT for assisting in the diagnosis of BCC.

Reduced OCT image quality is associated with superficial scales or crusting, although observer diagnostic performance with mediocre or better OCT image quality was still better than by clinical or dermoscopic assessment alone.

Nevertheless, it seems clear that extra care should be taken when superficial scales or crusting are present before deciding on a therapy.

All observers were able to judge their own diagnostic accuracy for a given lesion, downgrading their confidence in their decision when the OCT image quality was poor or the lesion characteristics less typical. Clearly, diagnostic confidence for

 Table 8 Proportion of histologically confirmed lesions of each subtype that were correctly identified

Accuracy	Nodular	Superficial	Infiltrative
Lesions (n)	50	78	13
Observer/clinical	46	77	38
Observer/dermoscopy	54	74	38
Observer/OCT	68	72	62
Regression model	58	78	23

each lesion depends not only on the quality of the OCT image and the difficulty of the lesion, but also on the experience of the observer. In this study, only experienced observers participated. Other workers have shown that diagnostic performance with OCT improves with observer experience.⁷

Based on this, we suggest that it might be useful practice, upon application of OCT, to assign a 'confidence level' in the diagnostic decision, e.g. very high, high, medium, low. This could then be used to determine further actions such as an additional biopsy. Also, if this information is documented systematically, it could also be used to track the increase in expertise of OCT image interpretation of the user over time.

The analysis of image markers and subtype identification shows that there are statistically significant correlations between image features and subtypes, although it is acknowledged that the sample size is rather small and these findings should be treated with caution. Table 7 summarizes these correlations. There are clear differences between characteristics of nodular, superficial and infiltrative BCCs, and observers were more accurate in identifying the specific subtype when using OCT than by clinical examination and dermoscopy alone.

For nodular BCCs, ovoid structures with cysts in the dermis are the most prominent marker, whereas for superficial BCCs, epidermal bulges intruding into the upper dermis, surrounded by a dark rim, are typical findings. These image markers for BCC have been previously reported by other workers.¹⁰⁻¹⁴ Infiltrative BCCs are characterized by ill-defined, narrow, dark, longish structures in the dermis, surrounded by brighter tissue, resembling a shoal of fish. These findings demonstrate that OCT visualizes the histopathology of architectural features of BCCs, i.e. the nodules and cysts of nodular BCCs, as well as the small tumours deriving from the basal epidermis in superficial BCCs and the irregular, ill-defined dermal tumour cords of infiltrative BCC, surrounded by a fibrotic stroma. This is in contrast to clinical examination and dermoscopy, where only the surface and very superficial findings can be assessed, lacking resolution and penetration depth.

Nevertheless, the diagnostic accuracy for each subtype was limited to 60–70%. However, it should be noted that the study excluded clinically obvious BCCs, suggesting that if OCT had been used on these types of BCC the diagnostic accuracy of defining the subtype would have been better.

Further image markers would be helpful; one possibility could be features observed in the *en face* images, which were not assessed in this study but have been examined elsewhere;^{14,15} another possibility could be vessel morphology in the lesions, which can be identified by the new dynamic OCT technology.^{16–19}

With regard to limitations, firstly, the sample size was limited to 234 lesions. For the analysis of further subcategories the sample size of certain subgroups was too small to enable definitive conclusions to be drawn and only indications and trends can be described. Furthermore, there are many types of non-BCC skin lesions, some of which could be 'confounders' for BCC, that were not seen in this trial. Therefore, it may be worthwhile repeating this trial with a larger sample size. Secondly, the study was performed by dermatologists experienced in noninvasive imaging. It is therefore not necessarily representative of the performance that would be achieved in routine use by nonspecialized dermatologists.

Thirdly, many of the observers' results, such as assessments of OCT image quality, their own diagnostic performance and the presence of specific image biomarkers, were somewhat subjective. Other observers might, using the same dataset, obtain different results by their own assessment, or with more quantitative image analysis methods and tools, although the results shown in Table 5 show a good degree of consistency between the observers in this study.

A study by Olsen et al. compared the diagnostic performance for actinic keratosis and BCC between a group of five dermatologists with experience in OCT image interpretation and five with no experience.⁷ They reported that skilled observers performed better than unskilled, and that there were no significant differences in interobserver agreement within each group. They also reported that high diagnostic accuracy was associated with higher observer confidence.

Fourthly, the histological results that provided the diagnostic standard might not be 100% accurate. Sixty-six per cent of the lesions were biopsied rather than excised, and the biopsy might in some cases have missed a tumour, leading to potential over-reporting of false positives by all three diagnostic methods, or – in the case of a 'mixed' BCC – an error in the accuracy of subtype identification.

Despite these limitations, we believe that the results of this study provide helpful implications for the standard of care and management of BCC using OCT.

For successful use of OCT, it is essential that physicians are trained in OCT scanning and image interpretation. It is helpful to note from Table 4 that diagnostic performance increases with observer confidence in their diagnosis. We expect, therefore, that OCT trainees will initially be able to diagnose BCCs with very obvious image features, and will steadily progress to less clear examples as their experience and expertise grow.

Further analysis of the data from this multicentre, prospective, observational, diagnostic trial of diagnosis of BCC with OCT has shown that: (i) OCT improves the differential diagnosis of BCC vs. other lesion types in clinically suspicious lesions, compared with clinical and dermoscopic diagnosis alone as reported previously; (ii) there are a number of useful 'image biomarkers' that aid the OCT user in diagnosing BCCs vs. other lesion types, but further research is needed to find additional new independent markers; (iii) poor OCT image quality is associated with superficial scales and crusting, and this affects the diagnostic performance of OCT, but diagnosis aided by OCT in these cases is still better than by clinical or dermoscopy examination alone; (iv) observers' own confidence in their diagnosis of BCC increased when using OCT vs. clinical and dermoscopy alone, and their actual diagnostic performance reflected this (i.e. they were more likely to be right when they had high confidence); (v) observer diagnostic performance was consistently better with OCT than with clinical examination or dermoscopy alone across all test sites. These conclusions support the targeted use of OCT to aid the diagnosis of BCC, potentially improving the standard of care by enabling more early-stage BCCs to be detected and by supporting the use of noninvasive treatment options.

References

- 1 Hussain AA, Themstrup L, Nürnberg BM et al. Adjunct use of optical coherence tomography increases the detection of recurrent basal cell carcinoma over clinical and dermoscopic examination alone. Photodiagnosis Photodyn Ther 2016; **14**:178–84.
- 2 Cheng HM, Lo S, Scolyer R et al. Accuracy of optical coherence tomography for the diagnosis of superficial basal cell carcinoma: a prospective, consecutive, cohort study of 168 cases. Br J Dermatol 2016; 175:1290–300.
- 3 Markowitz O, Schwartz M, Feldman E et al. Evaluation of optical coherence tomography as a means of identifying earlier stage basal cell carcinomas while reducing the use of diagnostic biopsy. J Clin Aesthet Dermatol 2015; **8**:14–20.
- 4 Ulrich M, Braunmuehl T, Kurzen H et al. The sensitivity and specificity of optical coherence tomography for the assisted diagnosis of nonpigmented basal cell carcinoma: an observational study. Br J Dermatol 2015; 173:428–35.
- 5 Cheng HM, Guitera P. Systematic review of optical coherence tomography usage in the diagnosis and management of basal cell carcinoma. Br J Dermatol 2015; 173:1371–80.
- 6 Holmes J, Hattersley S, Stone N et al. Multi-channel Fourier domain OCT system with superior lateral resolution for biomedical applications. Coherence Domain Optical Methods and Optical Coherence Tomography in Biomedicine XII, San Jose, CA, U.S.A., 28 February 2008. Proc. SPIE BiOS 6847; abstr. 68470O.
- 7 Olsen J, Themstrup L, De Carvalho N et al. Diagnostic accuracy of optical coherence tomography in actinic keratosis and basal cell carcinoma. Photodiagnosis Photodynam Ther 2016; 16:44–9.
- 8 Li G, Tietze JK, Tao X et al. High-definition optical coherence tomography in the diagnosis of basal cell carcinoma evaluated by an experienced versus in experienced investigator. J Clin Exp Dermatol Res 2014; 5:1000227.
- 9 Gambichler T, Jaedicke V, Terras S. Optical coherence tomography in dermatology: technical and clinical aspects. Arch Dermatol Res 2011; 303:457–73.
- 10 Boone MA, Norrenberg S, Jemec GB et al. Imaging of basal cell carcinoma by high-definition optical coherence tomography: histomorphological correlation. A pilot study. Br J Dermatol 2012; 167:856–64.
- 11 Gambichler T, Plura I, Kampilafkos P et al. Histopathological correlates of basal cell carcinoma in the slice and en face imaging modes of high-definition optical coherence tomography. Br J Dermatol 2014; 170:1358–61.
- 12 Meekings A, Utz S, Ulrich M et al. Differentiation of basal cell carcinoma subtypes in multi-beam swept source optical coherence tomography (MSS-OCT). J Drugs Dermatol 2016; 15:545.
- 13 Hussain AA, Themstrup L, Jemec GB. Optical coherence tomography in the diagnosis of basal cell carcinoma. Arch Dermatol Res 2015; 307:1–10.
- 14 Marneffe A, Suppa M, Miyamoto M et al. [High-definition optical coherence tomography: presentation of the technique and applications in dermatology]. Ann Dermatol Venereol 2015; 142:452–5 (in French).
- 15 Maier T, Braun-Falco M, Laubender RP et al. Actinic keratosis in the en-face and slice imaging mode of high-definition optical coherence tomography and comparison with histology. Br J Dermatol 2013; 168:120–8.

- 1110
- 16 Markowitz O, Schwartz M, Minhas S, Siegel DM. Speckle-variance optical coherence tomography: a novel approach to skin cancer characterization using vascular patterns. Dermatol Online J 2016; 22: pii: 13030/qt7w10290r.
- 17 De Carvalho N, Ciardo S, Cesinaro AM et al. In vivo micro-angiography by means of speckle-variance optical coherence tomography (SV-OCT) is able to detect microscopic vascular changes in naevus to melanoma transition. J Eur Acad Dermatol Venereol 2016; **30**: e67–8.
- 18 Ulrich M, Themstrup L, de Carvalho N et al. Dynamic optical coherence tomography in dermatology. Dermatology 2016; 232:298–311.
- 19 Schuh S, Holmes J, Ulrich M et al. Imaging blood vessel morphology in skin: dynamic optical coherence tomography as a novel potential diagnostic tool in dermatology. Dermatol Ther (Heidelb) 2017; 7:187–202.

Supporting Information

Additional Supporting Information may be found in the online version of this article at the publisher's website:

Video S1 Author video.

Powerpoint S1 Journal Club Slide Set.